Candel Therapeutics：取得進展並拓展更多路徑 (NASDAQ:CADL)
· seekingalpha.com
隨著 CAN-2409 在攝護腺癌治療領域接近向 FDA 提交申請，且有三期臨床數據與充裕的現金水位支撐，Candel Therapeutics, Inc. 維持「買入」評級。點擊查看 CADL 的最新動態。
I am now a contributor to Total Pharma Tracker, where you can join me for discussions, get my follow-ups on ideas, and specifically request ideas to explore. It...